Efficacy of capecitabine and temozolomide combination in well-differentiated neuroendocrine tumors: Jordan experience.
Options for the treatment of well-differentiated neuroendocrine tumors (NETs) are limited. We evaluated the efficacy of capecitabine and temozolomide combination in patients from Jordan. A retrospective review was conducted of 21 patients with metastatic well-differentiated NETs who failed somatostatin analogues and chemotherapy. Patients received capecitabine and temozolomide regimen every 28 days, and evaluation was done every 2 cycles. Twelve patients (57%) achieved partial response, and 5 (23%) achieved stable disease. Median progression-free survival was 16.5 months (range, 14.8-18 months). Of the 7 carcinoid tumors, 2 had partial response, and 2 had stable disease. There were no grade 4 toxicities or treatment-related deaths. Capecitabine and temozolomide regimen is an effective and well-tolerated salvage option for well-differentiated NETs.